Oncotelic Spotlighted in BioMedWire on $410B Drug-Delivery Market

Oncotelic Therapeutics (OTCQB: OTLC) has been featured in a BioMedWire editorial that examines the growing investor interest in platform biotech companies, especially as the global drug-delivery market is projected to reach an estimated $410 billion opportunity. The editorial underscores the industry's intensified focus on overcoming critical challenges such as drug penetration, tumor targeting, therapeutic resistance, and maintaining consistent intratumoral exposure. Oncotelic’s Sapu003 and Deciparticle platform are highlighted as pioneering nanotechnology-driven drug-delivery approaches designed to enhance the clinical utility of existing therapies through improved pharmacokinetics and delivery performance.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company boasts a robust pipeline, including directly owned drug candidates and a portfolio of inventions from its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Additionally, Oncotelic leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes. Beyond its internal programs, Oncotelic engages in strategic partnerships and joint ventures, such as its 45% interest in GMP Bio, which advances a complementary pipeline of therapeutic candidates.

The editorial also highlights the role of BioMedWire, a specialized communications platform focused on the latest developments in the Biotech, Biomedical Sciences, and Life Sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, enhanced press release distribution, and social media reach to millions of followers. The platform aims to cut through information overload, delivering breaking news and actionable content to investors, influencers, and the general public.